COVID-19: Current Challenges in ILD

C. Robalo Cordeiro (Coimbra, Portugal), M. Molina Molina (Barcelona, Spain), M. Wijsenbeek (Rotterdam, Netherlands)

Source: ERS webinar 2020: COVID-19: Current Challenges in ILD
Number: 0
Disease area: Interstitial lung diseases

WebcastSlide presentation

Rating: 4
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Robalo Cordeiro (Coimbra, Portugal), M. Molina Molina (Barcelona, Spain), M. Wijsenbeek (Rotterdam, Netherlands). COVID-19: Current Challenges in ILD. ERS webinar 2020: COVID-19: Current Challenges in ILD

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Interstital lung diseases: update 2005
Source: Annual Congress 2005 - Clinical year in review
Year: 2005

Idiopathic pulmonary fibrosis - IPF
Source: Respipedia Article
Year: 2018

Interstitial fibrosis with a nodule
Source: Annual Congress 2007 - Thoracic Oncology Grand Round: an interactive session
Year: 2007

Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom?
Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment
Year: 2006

Clinical case on ILD: a pulmonary case with many faces: not only interstitium
Source: Annual Congress 2007 - Clinical Grand Round: an interactive session
Year: 2007

Interstitial lung disease
Source: Eur Respir Rev 2013; 22: 26-32
Year: 2013

Pulmonary rehabilitation (PR) exercise tolerance improvement: Differences between interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2013 –Exercise, physiotherapy techniques and assessment in different chronic conditions
Year: 2013

Morphologic evaluation of lung in a scleroderma-like rabbit model
Source: Annual Congress 2006 - Systemic diseases, environmental and genetic factors in interstitial lung disease
Year: 2006

Bosentan in idiopathic pulmonary fibrosis (IPF): quality of life (QOL) results of the BUILD 1 study
Source: Annual Congress 2006 - Quality of life in various respiratory diseases
Year: 2006

Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013

Relevance of the expert ILD clinical-radiological evaluation of referred cases to the MDT
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016

Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry
Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Year: 2018

Genomic comparison of fibrotic rheumatoid arthritis-associated ILD and idiopathic pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015

Interstitial lung disease in elderly subjects
Source: Eur Respir Mon; 2009: 43: 150–162
Year: 2009

Contemporary surgical issues in NSCLC treatment
Source: Annual Congress 2007 - PG7 - Thoracic oncology: nonsmall cell lung cancer
Year: 2007

Pulmonary rehabilitation (PR) outcomes in chronic obstructive pulmonary disease (COPD) compared with interstitial lung disease (ILD)
Source: Annual Congress 2011 - Pulmonary rehabilitation: looking at alternative approaches and alternative populations beyond COPD
Year: 2011

Surfactant protein B polymorphisms, pulmonary function and COPD in 10,231 individuals
Source: Eur Respir J 2011; 37: 791-799
Year: 2011